Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
FP-based equilibrium competition assay from US Patent US11312722: "Hsp90 inhibitors and uses thereof"
Assay data:111 Active, 100 Activity ≤ 1 µM, 113 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µM
AlphaScreen Assay from Article 10.1021/cb400452z: "PIF-pocket as a target for C. albicans Pkh selective inhibitors."
Assay data:5 Tested
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
Protein Kinase Activity Assay from Article 10.1021/cb400452z: "PIF-pocket as a target for C. albicans Pkh selective inhibitors."
Assay data:1 Tested
Enzyme Assay from Article 10.1006/bioo.1997.1077: "Investigation of Mechanism of Nitrogen Transfer in Glucosamine 6-Phosphate Synthase with the Use of Transition State Analogs"
Assay data:15 Tested
Summary
Inhibition Assay from Article 10.1016/S1074-5521(02)00240-5: "Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors."
Assay data:6 Active, 1 Activity ≤ 1 nM, 5 Activity ≤ 1 µM, 6 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
CA Inhibition Assay from Article 10.1016/j.bmc.2009.05.002: "Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides."
Assay data:37 Active, 32 Activity ≤ 1 µM, 37 Tested
Enzyme Inhibition Assay from Article 10.1021/jm0101444: "X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor."
Assay data:5 Active, 5 Activity ≤ 1 µM, 5 Tested
Antifungal activity against Candida albicans infected in mouse assessed as reduction in necrotic cell fragments in intercellular spaces of the infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by hematoxyin-eosin staining based analysis
Assay data:3 Active, 3 Tested
SummaryCompounds, ActivePubMed Citation
Antifungal activity against Candida albicans infected in mouse assessed as disappearance of nuclear aggregation in the infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by hematoxyin-eosin staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as reduction in total amount of fungal cells in infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by hematoxyin-eosin staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as reduction in fungal proliferation in the infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by hematoxylin-eosin staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as reduction in fungal endogenous infection symptoms at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by hematoxylin-eosin staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as reduction in necrotic cell fragments in intercellular spaces of the infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by GMS staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as disappearance of nuclear aggregation in the infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by GMS staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as reduction in total amount of fungal cells in infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by GMS staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as reduction in fungal proliferation in the infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by GMS staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as reduction in fungal endogenous infection symptoms at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14 by GMS staining based analysis
Antifungal activity against Candida albicans infected in mouse assessed as shrinkage of fungal infection region at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14
Assay data:2 Active, 2 Tested
Antifungal activity against Candida albicans infected in mouse assessed as increase in animal's body weight at 20 mg/kg, ip administered on days 2,4,6,8,10,12 and measured on day 14
Inhibition of CYP51 in Candida albicans ATCC SC5314 assessed as unknown sterol content at 4 ug/ml measured after 48 hrs by GC-MS analysis
Assay data:4 Tested
SummaryPubMed CitationRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on